HARRISBURG, Pa.—MacuLogix Inc., an eye health company that provides eyecare professionals with instruments, tools and education to diagnose and treat patients with age-related macular degeneration (AMD), has completed a Series D round of financing totaling $38.7 million, according to an announcement Monday. New investor Vivo Capital led the investment round, with participation from existing investors Fisk Ventures, Roche Venture Fund, Berwind Private Equity and Life Sciences Greenhouse of Central Pennsylvania. The new funding will be used to further expand the MacuLogix team and company infrastructure to support the growing sales and practice integration efforts of the AdaptDx automated dark adaptometer, both domestically and internationally, the announcement noted.

MacuLogix has raised a total of $51 million in venture funding plus $10 million in venture debt as of this funding round, the announcement noted.

“AMD is the leading cause of adult blindness in the Western world because we haven’t had the technology or tools to effectively detect and manage this progressive, chronic disease – until now,” MacuLogix president and chief executive officer William D. McPhee said in the announcement. “Our company is determined to see AdaptDx functional testing become the standard of care, enabling eye care professionals to detect, treat and manage AMD earlier and more effectively.”

In conjunction with the new funding, Jack B. Nielsen, a managing director of Vivo Capital, Nathan Dau, principal of Vivo Capital, and Carole Nuechterlein, head of Roche Venture Fund, will join MacuLogix’s board of directors, according to the announcement. McPhee noted that the funding and the addition of Vivo Capital means that the company is “fully backed by a strategic group of investors who support our company’s vision to eliminate blindness caused by AMD.”

“MacuLogix is entering a rapid commercial expansion phase and is a very good fit for our investment strategy,” added Nielsen. “The AdaptDx is uniquely situated to help patients being diagnosed at an early stage of AMD and enable better and earlier monitoring and treatment of the disease.”